Among CSF1R inhibitors, though pexidartinib and edicotinib showed some clinical efficacy in tenosynovial giant cell tumors [307, 308], while most trials with CSF1R or CCR2 inhibitors were initiated with lacking preclinical evidence and modest clinical efficacy by reducing the number of circulating monocyte, TAMs and increasing the number of tumor T cell [309, 310]. The gene discussed is CSF1R; the disease is giant cell tumor.